<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arch Dermatol Res</journal-id>
      <journal-title>Archives of Dermatological Research</journal-title>
      <issn pub-type="ppub">0340-3696</issn>
      <issn pub-type="epub">1432-069X</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17492455</article-id>
      <article-id pub-id-type="pmc">1910889</article-id>
      <article-id pub-id-type="publisher-id">757</article-id>
      <article-id pub-id-type="doi">10.1007/s00403-007-0757-6</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Hot Clinical Study</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Weberschock</surname>
            <given-names>Tobias Bernd</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>M&#xFC;ller</surname>
            <given-names>Sylke-Monina</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Boehncke</surname>
            <given-names>Sandra</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Boehncke</surname>
            <given-names>Wolf-Henning</given-names>
          </name>
          <address>
            <phone>+49-69-63015743</phone>
            <fax>+49-69-63015117</fax>
            <email>Boehncke@em.uni-frankfurt.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Dermatology, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany </aff>
        <aff id="Aff2"><label>2</label>Department of Internal Medicine, Section for Endocrinology, Metabolism, and Diabetology, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>5</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>7</month>
        <year>2007</year>
      </pub-date>
      <volume>299</volume>
      <issue>4</issue>
      <fpage>169</fpage>
      <lpage>175</lpage>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>2</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>4</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Springer-Verlag 2007</copyright-statement>
      </permissions>
      <abstract>
        <p>Adverse events triggered by non-steroidal anti-inflammatory drugs (NSAIDs) are among the most common drug-related intolerance reactions in medicine; they are possibly related to inhibition of cyclooxygenase-1. Coxibs, preferentially inhibiting cyclooxygenase-2, may therefore represent safe alternatives in patients with NSAID intolerance. We reviewed the literature in a systematic and structured manner to identify and evaluate studies on the tolerance of coxibs in patients with NSAID intolerance. We searched MEDLINE (1966&#x2013;2006), the COCHRANE LIBRARY (4th Issue 2006) and EMBASE (1966&#x2013;2006) up to December 9, 2006, and analysed all publications included using a predefined evaluation sheet. Symptoms and severity of adverse events to coxibs were analysed based on all articles comprising such information. Subsequently, the probability for adverse events triggered by coxibs was determined on analyses of double-blind prospective trials only. Among 3,304 patients with NSAID intolerance, 119 adverse events occurred under coxib medication. All adverse events, except two, have been allergic/urticarial in nature; none was lethal, but two were graded as life-threatening (grade 4). The two non-allergic adverse events were described as a grade 1 upper respiratory tract haemorrhage, and a grade 1 gastrointestinal symptom, respectively. In 13 double-blind prospective studies comprising a total of 591 patients with NSAID intolerance, only 13 adverse reactions to coxib provocations were observed. The triggering coxibs were rofecoxib (2/286), celecoxib (6/208), etoricoxib (4/56), and valdecoxib (1/41). This review documents the good tolerability of coxibs in patients with NSAID intolerance, for whom access to this class of drugs for short-term treatment of pain and inflammation is advantageous.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Non-steroidal anti-inflammatory drugs</kwd>
        <kwd>Intolerance</kwd>
        <kwd>Urticaria</kwd>
        <kwd>Adverse drug reaction</kwd>
        <kwd>Coxibs</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2007</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly used therapeutics in the outpatient management of pain and inflammation in a wide spectrum of diseases. Their primary mode of action is the blockade of prostaglandin synthesis by cyclooxygenases (COX): Constitutively expressed COX-1 is involved in fundamental mechanisms of homeostasis, whereas the inducible COX-2 mediates inflammation. Therapeutic effects of NSAIDs are primarily related to their ability to inhibit COX-2, whereas some of their most frequent adverse effects may be caused by COX-1 inhibition (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). In contrast to most &#x201C;classic&#x201D; NSAIDs which block both isoforms, the so-called coxibs preferentially inhibit COX-2. This may result in better tolerability, namely reduction of gastrointestinal side effects [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR85">85</xref>].
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Cyclooxygenase isoforms. Non-steroidal anti-inflammatory drugs (<italic>NSAIDs</italic>) block prostaglandin synthesis by cyclooxygenases (<italic>COX</italic>). Two isoforms exist of this enzyme: constitutively expressed COX-1 is involved in fundamental mechanisms of homeostasis, whereas the inducible isoform COX-2 mediates inflammation</p></caption><graphic position="anchor" xlink:href="403_2007_757_Fig1_HTML" id="MO1"/></fig></p>
      <p>Respiratory and cutaneous adverse events triggered by NSAIDs are among the most common drug-related intolerance reactions in medicine. Typically, these manifest as asthma attacks or urticaria. Pathogenesis of these symptoms seems to be related to COX-1 inhibition [<xref ref-type="bibr" rid="CR76">76</xref>]. Therefore, the hypothesis was put forward that coxibs may safely be used in patients with known NSAID intolerance. However, serious intolerance reactions to coxibs have also been observed, thus cautioning too euphoric expectations [<xref ref-type="bibr" rid="CR71">71</xref>]. We therefore reviewed the relevant literature in a systematic and structured approach for evidence of coxib tolerance in patients with NSAID intolerance.</p>
    </sec>
    <sec id="Sec2" sec-type="methods">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Search strategy</title>
        <p>We searched MEDLINE (1966&#x2013;2006), the COCHRANE LIBRARY (4th Issue 2006) and EMBASE (1966&#x2013;2006) up to December 9, 2006. The following search terms were used: rofecoxib OR celecoxib OR valdecoxib OR parecoxib OR etoricoxib, combined with hypersensitivity OR intolerance. Those coxibs used in veterinary medicine (deracoxib, tiracoxib and cimicoxib) were not included in the literature search. No language or publication restriction was predefined. All publications reporting individual patients with NSAID intolerance and subsequent exposure to a COX-2 Inhibitor were identified and the reference lists of these articles were hand-searched for further publications. If articles could not be retrieved in full text, a copy was requested from the corresponding author and/or journal editor.</p>
      </sec>
      <sec id="Sec4">
        <title>Inclusion criteria</title>
        <p>Each publication was appraised for inclusion in a stepwise approach (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). Only publications describing individual patients and providing a rational medication scheme as well as a sufficiently specific outcome report were included in this review. In a first step, evaluation focused on clinical symptoms and severity of adverse events in patients with NSAID intolerance. Therefore, all articles on this topic were included for this analysis. Subsequently, the probability for adverse events was analysed based exclusively on publications of double-blind prospective trials.
<fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>Flow chart documenting the handling data (<italic>NSAID</italic> non-steroidal anti-inflammatory drugs)</p></caption><graphic position="anchor" xlink:href="403_2007_757_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
      <sec id="Sec5">
        <title>Data extraction and synthesis</title>
        <p>All articles were analysed using a predefined evaluation sheet. Uncertainties were resolved by consensus decisions among the investigators. Data synthesis was qualitative and descriptive. The Common Terminology Criteria for Adverse Events version 3.0 (CTCAE) was used to categorize adverse events.</p>
      </sec>
    </sec>
    <sec id="Sec6" sec-type="results">
      <title>Results</title>
      <p>We identified 230 publications on coxibs and/or NSAID intolerance. Hundred and forty-six references not focusing on individual patients with NSAID intolerance were excluded. Unclear medication schemes or outcome reports led to exclusion of two articles. Eighty-four publications were evaluated for severity and type of adverse reactions to coxibs. Thirteen publications on double-blind studies were used to determine the probability of adverse reactions to coxibs.</p>
      <sec id="Sec7">
        <title>Severity and type of adverse events to coxibs</title>
        <p>A total of 119 adverse events among 3,304 patients exposed to coxibs were identified [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR20">20</xref>&#x2013;<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR26">26</xref>&#x2013;<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>&#x2013;<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR37">37</xref>&#x2013;<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR60">60</xref>&#x2013;<xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR77">77</xref>&#x2013;<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR86">86</xref>&#x2013;<xref ref-type="bibr" rid="CR89">89</xref>]. Adverse events were described for rofecoxib (48/1,732), celecoxib (59/1,148), etoricoxib (10/328), and valdecoxib (2/69), but not parecoxib (0/27) (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). All adverse events, except two, have been allergic/urticarial in nature, and none was lethal. One adverse event after administration of rofecoxib and one after celecoxib were reported as life-threatening (grade 4). The two non-allergic adverse events were described as a grade 1 upper respiratory tract haemorrhage, namely blood in nasal discharge after provocation with rofecoxib, and a grade 1 gastrointestinal symptom, namely nausea and abdominal pain.
<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Mode and severity of adverse event (<italic>CTCAE</italic> common terminology criteria for adverse events)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Patients</th><th align="left">Events (total)</th><th align="left">Urticaria (grade)</th><th align="left">Allergic reactions (grade) </th><th align="left">Allergic rhinitis (grade)</th><th align="left">Airway obstruction (grade)</th><th align="left">Gastroin-testinal symtpms (grade)</th><th align="left">Pruritus (grade)</th><th align="left">Hemorrhage, upper respiratory (grade)</th></tr></thead><tbody><tr><td align="left">Rofecoxib</td><td char="." align="char">1,732</td><td align="left">48</td><td align="left">9 (1)<break/>8 (2)<break/>1 (3)</td><td align="left">25 (3)<break/>1 (4)</td><td align="left">1 (2)</td><td align="left">2 (1)</td><td align="left">0</td><td align="left">0</td><td align="left">1 (1)</td></tr><tr><td align="left">Celecoxib</td><td char="." align="char">1,148</td><td align="left">59</td><td align="left">19 (1)<break/>1 (2)</td><td align="left">1 (2)<break/>33 (3)<break/>1 (4)</td><td align="left">0</td><td align="left">1 (1)</td><td align="left">0</td><td align="left">3 (2)</td><td align="left">0</td></tr><tr><td align="left">Etoricoxib</td><td char="." align="char">328</td><td align="left">10</td><td align="left">3 (1)<break/>5 (2)</td><td align="left">1 (3)</td><td align="left">0</td><td align="left">0</td><td align="left">1 (1)</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Valdecoxib</td><td char="." align="char">69</td><td align="left">2</td><td align="left">1 (1)<break/>1 (2)</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Parecoxib</td><td char="." align="char">27</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Total</td><td char="." align="char">3,304</td><td align="left">119</td><td align="left">48</td><td align="left">62</td><td align="left">1</td><td align="left">3</td><td align="left">1</td><td align="left">3</td><td align="left">1</td></tr></tbody></table><table-wrap-foot><p>Numbers and grade of adverse events (in parentheses) are indicated</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec8">
        <title>Evaluation of double-blind studies</title>
        <p>We identified 13 double-blind studies evaluating tolerability of coxibs in a total of 591 NSAID intolerant patients (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>). The coxibs tested in the context of these studies were rofecoxib (<italic>n</italic>&#xA0;=&#xA0;286), celecoxib (<italic>n</italic>&#xA0;=&#xA0;208), etoricoxib (<italic>n</italic>&#xA0;=&#xA0;56) and valdecoxib (<italic>n</italic>&#xA0;=&#xA0;41). Among the 591 patients described, 13 exhibited adverse reactions upon provocation with a coxib. The triggering coxibs were rofecoxib (2/286), celecoxib (6/208), etoricoxib (4/56), and valdecoxib (1/41) [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. One of these reactions was clearly non-allergic, this one being the above-mentioned individual with grade 1 upper respiratory tract haemorrhage.
<table-wrap id="Tab2"><label>Table&#xA0;2</label><caption><p>Snopsis of double blind studies (<italic>NSAID</italic> non-steroidal anti-inflammatory drugs)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">References</th><th align="left">Substance (number of patients)</th><th align="left">Dose</th><th align="left">Oral provocation with NSAID</th><th align="left">Follow-up</th><th align="left">Adverse events (number of patients/grade)</th></tr></thead><tbody><tr><td align="left">[<xref ref-type="bibr" rid="CR87">87</xref>]</td><td align="left">Celecoxib (17)</td><td align="left">Celecoxib 200&#xA0;mg</td><td align="left">Yes</td><td align="left">Clinical examinations and forced expiratory volume hourly for 8&#xA0;h.</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR74">74</xref>]</td><td align="left">Celecoxib (12)/rofecoxib (3)</td><td align="left">Celecoxib 200&#xA0;mg/rofecoxib 12.5&#xA0;mg</td><td align="left">Yes</td><td align="left">No information</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR75">75</xref>]</td><td align="left">Rofecoxib (60)</td><td align="left">Rofecoxib 37.5&#xA0;mg total dose</td><td align="left">Yes</td><td align="left">Clinical examinations and flow/volume recording hourly</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR77">77</xref>]</td><td align="left">Rofecoxib (12)</td><td align="left">Rofecoxib 25&#xA0;mg</td><td align="left">Yes</td><td align="left">Clinical observation every 30&#xA0;min for 8&#xA0;h and finally after 24&#xA0;h.</td><td align="left">Traces of blood in nasal discharge on days 3&#x2013;5 of rofecoxib administration (1/1), transient urticaria for 30&#xA0;min after administration of 5&#xA0;mg rofecoxib, but not after further administration of higher doses of the drug (1/1)</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR78">78</xref>]</td><td align="left">Celecoxib (14)<break/>Rofecoxib 10</td><td align="left">Celecoxib 200&#x2013;400&#xA0;mg total dose<break/> Rofecoxib 37.5&#xA0;mg total dose</td><td align="left">Yes</td><td align="left">Forced expiratory volume was recorded each hour for 3&#xA0;h</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR60">60</xref>]</td><td align="left">Rofecoxib (104)</td><td align="left">Rofecoxib 25&#xA0;mg total dose</td><td align="left">Yes</td><td align="left">Clinical control for at least 6&#xA0;h after each challenge and the next day.</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR83">83</xref>]</td><td align="left">Celecoxib (60)</td><td align="left">Celecoxib 200&#xA0;mg</td><td align="left">Yes</td><td align="left">Clinical examinations were conducted hourly</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR28">28</xref>]</td><td align="left">Celecoxib (33)</td><td align="left">Celecoxib 130&#xA0;mg total dose</td><td align="left">Yes</td><td align="left">Spirometry and vital signs at 15- to 30-min intervals after each dose.</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR88">88</xref>]</td><td align="left">Celecoxib (18)/rofecoxib (18)</td><td align="left">Celecoxib 300&#xA0;mg total dose/rofecoxib 37.5&#xA0;mg total dose1</td><td align="left">Yes</td><td align="left">Vital signs and forced expiratory volume every 15&#xA0;min for 6&#xA0;h.</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR84">84</xref>]</td><td align="left">Rofecoxib (60)</td><td align="left">Rofecoxib 50&#xA0;mg</td><td align="left">Yes</td><td align="left">Clinical examinations and forced expiratory volume hourly.</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR13">13</xref>]</td><td align="left">Valdecoxib (41)</td><td align="left">Valedcoxib 30&#xA0;mg total dose</td><td align="left">Yes</td><td align="left">Clinical examination and monitoring of pulse/blood pressare until 16&#xA0;h past last exposure</td><td align="left">Generalised urticaria (1/2)</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]</td><td align="left">Celecoxib (54)<break/>Etoricoxib (56)</td><td align="left">Celecoxib 200&#xA0;mg<break/>Etoricoxib 120&#xA0;mg</td><td align="left">Yes</td><td align="left">Vital signs and pulmonary function was monitored at baseline and hourly for 3&#xA0;h and the skin, nose, thorax were examined at the same intervals</td><td align="left">Celecoxib: urticaria (3/1), lip angioedema (1/3), eyelid wheals and angioedema (1/3), urticaria, rhinorrhea, and conjunctival injection (1/1)<break/>etoricoxib: urticaria (3/1), tongue, eyelid and lip angioedema (1/3)</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left">Rofecoxib (19)</td><td align="left">Rofecoxib 37.5&#xA0;mg total dose</td><td align="left">Yes</td><td align="left">Serial measurement of forced expiratory volume after 30, 60 and 120&#xA0;min</td><td align="left">0</td></tr></tbody></table></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec9" sec-type="discussion">
      <title>Discussion</title>
      <p>This systematic review documents the low probability of allergic/pseudo-allergic reactions induced by coxibs in patients with NSAID intolerance. To our knowledge, this is the first comprehensive analysis of data published on this topic. We have searched all three major medical databases available, namely MEDLINE, COCHRANE LIBRARY, and EMBASE using very broad and general search terms. Following identification of relevant publications, these were evaluated by means of a pre-defined evaluation form. The data available are described in the form of a structured review [<xref ref-type="bibr" rid="CR19">19</xref>].</p>
      <p>NSAIDs are among the most commonly prescribed therapeutics in the world. Although generally considered safe, their wide and frequent use results in these drugs being among the most common causes of drug-related intolerance reactions. This may at least in part be due to their non-selective inhibition of both cyclooxygenase isoforms. In line with this hypothesis, NSAIDs characterized by pronounced COX-1 inhibition bear a high risk to trigger asthma attacks in patients with aspirin-sensitive asthma bronchiale, whereas preferentially COX-2 inhibiting NSAIDS are better tolerated by these patients [<xref ref-type="bibr" rid="CR36">36</xref>]. Our analysis of published studies on this issue further supports this notion, as only 13 of 591 NSAID-intolerant patients showed adverse reactions upon provocation with coxibs in double-blind clinical studies; all of these were grade 3 or milder. Still, relatively selective COX-2 inhibitors have been identified as triggers of serious intolerance reactions [<xref ref-type="bibr" rid="CR71">71</xref>]. This implies that our current understanding of NSAID-triggered intolerance is still imperfect, and its pathogenesis cannot be reduced to cyclooxygenase-mediated effects alone, but needs to take into account clinically relevant additional NSAID-mediated effects such as secretion of leukotrienes from mast cells and other leukocytes.</p>
      <p>It has been suggested that coxibs may confer an elevated risk for acute myocardial infarction and sudden cardiac death, namely after long-term therapy [<xref ref-type="bibr" rid="CR25">25</xref>]. As a reaction, several coxibs are no longer available despite a recommendation by the participants of an expert meeting organized by the Food and Drug Administration to grant further prescription of rofecoxib, celecoxib and valdecoxib in the US [<xref ref-type="bibr" rid="CR59">59</xref>]. On the other hand, substantial evidence described here points towards a good tolerability of coxibs in patients with NSAID intolerance. Given the wide use of NSAIDs in the short-term treatment of trivial signs and symptoms, the availability of coxibs for these indications would be advantageous for this relevant subpopulation of patients, since this type of application is unlikely to increase cardiac risk.</p>
    </sec>
  </body>
  <back>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahlbach</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Usadel</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Kaufmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Boehncke</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
          <article-title>The selective cyclooxygenase-2 inhibitor celecoxib is a safe alternative in patients with pseudo-allergic reactions to nonsteroidal anti-inflammatory drugs</article-title>
          <source>Med Klin (Munich)</source>
          <year>2003</year>
          <volume>98</volume>
          <fpage>242</fpage>
          <lpage>244</lpage>
          <pub-id pub-id-type="doi">10.1007/s00063-003-1251-3</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ahlbach S, Usadel KH, Kaufmann R, Boehncke WH (2003) The selective cyclooxygenase-2 inhibitor celecoxib is a safe alternative in patients with pseudo-allergic reactions to nonsteroidal anti-inflammatory drugs. Med Klin (Munich) 98:242&#x2013;244 <pub-id pub-id-type="pmid">12721666</pub-id></citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andri</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Safety of celecoxib in patients with ASA/NSAIDs sensitivity (abstract)</article-title>
          <source>Allergy</source>
          <year>2001</year>
          <volume>56</volume>
          <fpage>223</fpage>
        </citation>
        <citation citation-type="display-unstructured">Andri L (2001) Safety of celecoxib in patients with ASA/NSAIDs sensitivity (abstract). Allergy 56:223 </citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Asero</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Tolerability of rofecoxib</article-title>
          <source>Allergy Eur J Allergy Clin Immunol</source>
          <year>2001</year>
          <volume>56</volume>
          <fpage>916</fpage>
          <lpage>917</lpage>
          <pub-id pub-id-type="doi">10.1034/j.1398-9995.2001.00300.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Asero R (2001) Tolerability of rofecoxib. Allergy Eur J Allergy Clin Immunol 56:916&#x2013;917 </citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Asero</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Chronic urticaria with multiple NSAID intolerance: Is tramadol always a safe alternative analgesic?</article-title>
          <source>J Investig Allergol Clin Immunol</source>
          <year>2003</year>
          <volume>13</volume>
          <fpage>56</fpage>
          <lpage>59</lpage>
        </citation>
        <citation citation-type="display-unstructured">Asero R (2003) Chronic urticaria with multiple NSAID intolerance: Is tramadol always a safe alternative analgesic? J Investig Allergol Clin Immunol 13:56&#x2013;59 <pub-id pub-id-type="pmid">12861852</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Asero</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs</article-title>
          <source>Clin Exp Allergy</source>
          <year>2005</year>
          <volume>35</volume>
          <fpage>713</fpage>
          <lpage>716</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2222.2005.2228.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Asero R (2005) Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs. Clin Exp Allergy 35:713&#x2013;716 <pub-id pub-id-type="pmid">15969659</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Asero</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria</article-title>
          <source>Ann Allergy Asthma Immunol</source>
          <year>2006</year>
          <volume>97</volume>
          <fpage>187</fpage>
          <lpage>189</lpage>
        </citation>
        <citation citation-type="display-unstructured">Asero R (2006) Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria. Ann Allergy Asthma Immunol 97:187&#x2013;189 <pub-id pub-id-type="pmid">16937749</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Asero</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tedeschi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lorini</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Autoreactivity is highly prevalent in patients with multiple intolerances to NSAIDs</article-title>
          <source>Ann Allergy Asthma Immunol</source>
          <year>2002</year>
          <volume>88</volume>
          <fpage>468</fpage>
          <lpage>472</lpage>
        </citation>
        <citation citation-type="display-unstructured">Asero R, Tedeschi A, Lorini M (2002) Autoreactivity is highly prevalent in patients with multiple intolerances to NSAIDs. Ann Allergy Asthma Immunol 88:468&#x2013;472 <pub-id pub-id-type="pmid">12027067</pub-id></citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baldassarre</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schandene</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Choufani</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Michils</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Asthma attacks induced by low doses of celecoxib, aspirin, and acetaminophen</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2006</year>
          <volume>117</volume>
          <fpage>215</fpage>
          <lpage>217</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2005.10.021</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Baldassarre S, Schandene L, Choufani G, Michils A (2006) Asthma attacks induced by low doses of celecoxib, aspirin, and acetaminophen. J Allergy Clin Immunol 117:215&#x2013;217 <pub-id pub-id-type="pmid">16387610</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bavbek</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Celik</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ozer</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mungan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Misirligil</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib</article-title>
          <source>J Asthma</source>
          <year>2004</year>
          <volume>41</volume>
          <fpage>67</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="doi">10.1081/JAS-120026063</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z (2004) Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. J Asthma 41:67&#x2013;75 <pub-id pub-id-type="pmid">15046380</pub-id></citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bavbek</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Celik</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pasaoglu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Misirligil</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients</article-title>
          <source>J Investig Allergol Clin Immunol</source>
          <year>2006</year>
          <volume>16</volume>
          <fpage>57</fpage>
          <lpage>62</lpage>
        </citation>
        <citation citation-type="display-unstructured">Bavbek S, Celik G, Pasaoglu G, Misirligil Z (2006) Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients. J Investig Allergol Clin Immunol 16:57&#x2013;62 <pub-id pub-id-type="pmid">16599250</pub-id></citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berges-Gimeno</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Camacho-Garrido</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Garcia-Rodriguez</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Alfaya</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Martin Garcia</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hinojosa</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Rofecoxib safe in NSAID hypersensitivity</article-title>
          <source>Allergy Eur J Allergy Clin Immunol</source>
          <year>2001</year>
          <volume>56</volume>
          <fpage>1017</fpage>
          <lpage>1018</lpage>
          <pub-id pub-id-type="doi">10.1034/j.1398-9995.2001.00206.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Berges-Gimeno MP, Camacho-Garrido E, Garcia-Rodriguez RM, Alfaya T, Martin Garcia C, Hinojosa M (2001) Rofecoxib safe in NSAID hypersensitivity. Allergy Eur J Allergy Clin Immunol 56:1017&#x2013;1018 </citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bochenek</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Nizankowska</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mejza</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sierczynska</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Szczeklik</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Good tolerance of rofecoxib in aspirin-induced asthma.</article-title>
          <source>Eur Respir J</source>
          <year>2001</year>
          <volume>18</volume>
          <fpage>424s</fpage>
        </citation>
        <citation citation-type="display-unstructured">Bochenek G, Nizankowska E, Mejza F, Sierczynska M, Szczeklik A (2001) Good tolerance of rofecoxib in aspirin-induced asthma. Eur Respir J 18:424s </citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boehncke</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Boehncke</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
          <article-title>Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs)</article-title>
          <source>Dtsch Med Wochenschr</source>
          <year>2005</year>
          <volume>130</volume>
          <fpage>2249</fpage>
          <lpage>2252</lpage>
          <pub-id pub-id-type="doi">10.1055/s-2005-918556</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Boehncke S, Boehncke WH (2005) Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs). Dtsch Med Wochenschr 130:2249&#x2013;2252 <pub-id pub-id-type="pmid">16208597</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carretero</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Perez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Garces</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
          <article-title>Tolerance to Celecovix in patients with NSAID intolerance (abstract)</article-title>
          <source>Allergy</source>
          <year>2007</year>
          <volume>56</volume>
          <fpage>222</fpage>
        </citation>
        <citation citation-type="display-unstructured">Carretero P, Perez R, Garces MM (2007) Tolerance to Celecovix in patients with NSAID intolerance (abstract). Allergy 56:222 </citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Celik</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Erkekol</surname>
              <given-names>FO</given-names>
            </name>
            <name>
              <surname>Bavbek</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dursun</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Misirligil</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Long-term use and tolerability of cyclooxygenase-2 inhibitors in patients with analgesic intolerance</article-title>
          <source>Ann Allergy Asthma Immunol</source>
          <year>2005</year>
          <volume>95</volume>
          <fpage>33</fpage>
          <lpage>37</lpage>
        </citation>
        <citation citation-type="display-unstructured">Celik G, Erkekol FO, Bavbek S, Dursun B, Misirligil Z (2005) Long-term use and tolerability of cyclooxygenase-2 inhibitors in patients with analgesic intolerance. Ann Allergy Asthma Immunol 95:33&#x2013;37 <pub-id pub-id-type="pmid">16095139</pub-id></citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Celik</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pasaoglu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bavbek</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Abadoglu</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Dursun</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Mungan</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance</article-title>
          <source>J Asthma</source>
          <year>2005</year>
          <volume>42</volume>
          <fpage>127</fpage>
          <lpage>131</lpage>
        </citation>
        <citation citation-type="display-unstructured">Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D et al (2005) Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma 42:127&#x2013;131 <pub-id pub-id-type="pmid">15871445</pub-id></citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dahlen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Szczeklik</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group</article-title>
          <source>N Engl J Med</source>
          <year>2001</year>
          <volume>344</volume>
          <fpage>S142</fpage>
          <pub-id pub-id-type="doi">10.1056/NEJM200101113440215</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Dahlen B, Szczeklik A, Murray JJ (2001) Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group. N Engl J Med 344:S142 </citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="other">Dama AR, Lobefalo G, Bonadona P, Schiappoli M, Crivellaro M (2002) Celecoxib, a new selective COX-2 Inhibitor is a safe alternative drug in NSAID-intolerant patients (abstract). J Allergy Clin Immunol S141</citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Egger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Sterne</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Uses and abuses of meta-analysis</article-title>
          <source>Clin Med</source>
          <year>2001</year>
          <volume>1</volume>
          <fpage>478</fpage>
          <lpage>484</lpage>
        </citation>
        <citation citation-type="display-unstructured">Egger M, Smith GD, Sterne JA (2001) Uses and abuses of meta-analysis. Clin Med 1:478&#x2013;484 <pub-id pub-id-type="pmid">11792089</pub-id></citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>El Miedany</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Youssef</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>El Gaafary</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease</article-title>
          <source>Ann Allergy Asthma Immunol</source>
          <year>2006</year>
          <volume>97</volume>
          <fpage>105</fpage>
          <lpage>109</lpage>
        </citation>
        <citation citation-type="display-unstructured">El Miedany Y, Youssef S, Ahmed I, El Gaafary M (2006) Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 97:105&#x2013;109 <pub-id pub-id-type="pmid">16892790</pub-id></citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Enrique</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Cistero-Bahima</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Miguel-Moncin</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Alonso</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Rofecoxib should be tried in NSAID hypersensitivity</article-title>
          <source>Allergy</source>
          <year>2000</year>
          <volume>55</volume>
          <fpage>1090</fpage>
          <pub-id pub-id-type="doi">10.1034/j.1398-9995.2000.00838.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Enrique E, Cistero-Bahima A, Miguel-Moncin MM, Alonso R (2000) Rofecoxib should be tried in NSAID hypersensitivity. Allergy 55:1090 <pub-id pub-id-type="pmid">11097321</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fernandez-Melendez</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Miranda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carmona</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Diaz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Barcelo</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Vega</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tolerance of rofecoxib in patients with adverse reactions to nonsteroidal ant-inflammatory drugs (NSAIDs)</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2002</year>
          <volume>109</volume>
          <fpage>S140</fpage>
          <pub-id pub-id-type="doi">10.1016/S0091-6749(02)81546-9</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fernandez-Melendez S, Miranda A, Carmona MJ, Diaz J, Barcelo JM, Vega JM et al (2002) Tolerance of rofecoxib in patients with adverse reactions to nonsteroidal ant-inflammatory drugs (NSAIDs). J Allergy Clin Immunol 109:S140 </citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garcia-Rodriguez</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Hinojosa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Camacho-Garrido</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Berges</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>GC</given-names>
            </name>
          </person-group>
          <article-title>Celecoxib, safe in NSAID intolerance</article-title>
          <source>Allergy</source>
          <year>2002</year>
          <volume>57</volume>
          <fpage>1085</fpage>
          <lpage>1086</lpage>
          <pub-id pub-id-type="doi">10.1034/j.1398-9995.2002.23836_7.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Garcia-Rodriguez RM, Hinojosa M, Camacho-Garrido E, Berges GP, Martin GC (2002) Celecoxib, safe in NSAID intolerance. Allergy 57:1085&#x2013;1086 <pub-id pub-id-type="pmid">12359017</pub-id></citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Giamarchi</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Escamilla</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Carme</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Krempf</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Selective COX-2 inhibitors: a safety alternative for patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs) (abstract)</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2004</year>
          <volume>113</volume>
          <fpage>S180</fpage>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2004.01.085</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Giamarchi D, Escamilla R, Carme S, Krempf M (2004) Selective COX-2 inhibitors: a safety alternative for patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs) (abstract). J Allergy Clin Immunol 113:S180 </citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Graham</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Campen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hui</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Spence</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cheetham</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study</article-title>
          <source>Lancet</source>
          <year>2005</year>
          <volume>365</volume>
          <fpage>475</fpage>
          <lpage>481</lpage>
        </citation>
        <citation citation-type="display-unstructured">Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G et al (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365:475&#x2013;481 <pub-id pub-id-type="pmid">15705456</pub-id></citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grimm</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Rakoski</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ring</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Urticaria and angioedema induced by COX-2 inhibitors</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2002</year>
          <volume>109</volume>
          <fpage>370</fpage>
          <pub-id pub-id-type="doi">10.1067/mai.2002.121315</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Grimm V, Rakoski J, Ring J (2002) Urticaria and angioedema induced by COX-2 inhibitors. J Allergy Clin Immunol 109:370 <pub-id pub-id-type="pmid">11842312</pub-id></citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grob</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pichler</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Wuthrich</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Anaphylaxis to celecoxib</article-title>
          <source>Allergy</source>
          <year>2002</year>
          <volume>57</volume>
          <fpage>264</fpage>
          <lpage>265</lpage>
          <pub-id pub-id-type="doi">10.1034/j.1398-9995.2002.1n3581.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Grob M, Pichler WJ, Wuthrich B (2002) Anaphylaxis to celecoxib. Allergy 57:264&#x2013;265 <pub-id pub-id-type="pmid">11906348</pub-id></citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gyllfors</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bochenek</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Overholt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Drupka</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kumlin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sheller</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2003</year>
          <volume>111</volume>
          <fpage>1116</fpage>
          <lpage>1121</lpage>
          <pub-id pub-id-type="doi">10.1067/mai.2003.1450</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Gyllfors P, Bochenek G, Overholt J, Drupka D, Kumlin M, Sheller J et al (2003) Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 111:1116&#x2013;1121 <pub-id pub-id-type="pmid">12743579</pub-id></citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hawkey</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <article-title>COX-2 inhibitors</article-title>
          <source>Lancet</source>
          <year>1999</year>
          <volume>353</volume>
          <fpage>307</fpage>
          <lpage>314</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(98)12154-2</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hawkey CJ (1999) COX-2 inhibitors. Lancet 353:307&#x2013;314 <pub-id pub-id-type="pmid">9929039</pub-id></citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hinrichs</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ritzkowsky</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hunzelmann</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Krieg</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Scharffetter-Kochanek</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Rofecoxib as an alternative in aspirin hypersensitivity</article-title>
          <source>Allergy</source>
          <year>2001</year>
          <volume>56</volume>
          <fpage>789</fpage>
          <pub-id pub-id-type="doi">10.1034/j.1398-9995.2001.056008789.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hinrichs R, Ritzkowsky A, Hunzelmann N, Krieg T, Scharffetter-Kochanek K (2001) Rofecoxib as an alternative in aspirin hypersensitivity. Allergy 56:789 <pub-id pub-id-type="pmid">11488679</pub-id></citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hinrichs</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ritzkowsky</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hunzelmann</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Scharffetter-Kochanek</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Cox-2 inhibitors - An alternative in analgesic intolerance</article-title>
          <source>H G Z Hautkr</source>
          <year>2001</year>
          <volume>76</volume>
          <fpage>126</fpage>
          <lpage>127</lpage>
        </citation>
        <citation citation-type="display-unstructured">Hinrichs R, Ritzkowsky A, Hunzelmann N, Scharffetter-Kochanek K (2001) Cox-2 inhibitors - An alternative in analgesic intolerance. H G Z Hautkr 76:126&#x2013;127 </citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalyoncu</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Karakaya</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bozkurt</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Artvinli</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>A new method of oral drug provocation testing for determining safe alternatives for patients with non-steroidal anti-inflammatory drug intolerance: the triple test</article-title>
          <source>Int Arch Allergy Immunol</source>
          <year>2005</year>
          <volume>138</volume>
          <fpage>319</fpage>
          <lpage>323</lpage>
          <pub-id pub-id-type="doi">10.1159/000088870</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kalyoncu AF, Karakaya G, Bozkurt B, Artvinli M (2005) A new method of oral drug provocation testing for determining safe alternatives for patients with non-steroidal anti-inflammatory drug intolerance: the triple test. Int Arch Allergy Immunol 138:319&#x2013;323 <pub-id pub-id-type="pmid">16224191</pub-id></citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karakaya</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kalyoncu</surname>
              <given-names>AF</given-names>
            </name>
          </person-group>
          <article-title>Safety of nimesulide, meloxicam and rofecoxib as alternative analgesics</article-title>
          <source>Allergol Immunopathol (Madr)</source>
          <year>2000</year>
          <volume>28</volume>
          <fpage>319</fpage>
          <lpage>321</lpage>
        </citation>
        <citation citation-type="display-unstructured">Karakaya G, Kalyoncu AF (2000) Safety of nimesulide, meloxicam and rofecoxib as alternative analgesics. Allergol Immunopathol (Madr) 28:319&#x2013;321 <pub-id pub-id-type="pmid">11269899</pub-id></citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelkar</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Butterfield</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Teaford</surname>
              <given-names>HG</given-names>
            </name>
          </person-group>
          <article-title>Urticaria and angioedema from cyclooxygenase-2 inhibitors</article-title>
          <source>J Rheumatol</source>
          <year>2001</year>
          <volume>28</volume>
          <fpage>2553</fpage>
          <lpage>2554</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kelkar PS, Butterfield JH, Teaford HG (2001) Urticaria and angioedema from cyclooxygenase-2 inhibitors. J Rheumatol 28:2553&#x2013;2554 <pub-id pub-id-type="pmid">11708434</pub-id></citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kleinhans</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Linzbach</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zedlitz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kaufmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Boehncke</surname>
              <given-names>W-H</given-names>
            </name>
          </person-group>
          <article-title>Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation</article-title>
          <source>Contact Dermatitis</source>
          <year>2002</year>
          <volume>47</volume>
          <fpage>100</fpage>
          <lpage>102</lpage>
          <pub-id pub-id-type="doi">10.1034/j.1600-0536.2002.470208.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kleinhans M, Linzbach L, Zedlitz S, Kaufmann R, Boehncke W-H (2002) Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation. Contact Dermatitis 47:100&#x2013;102 <pub-id pub-id-type="pmid">12423408</pub-id></citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kosnik</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Music</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Matjaz</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Suskovic</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Relative safety of meloxicam in NSAID-intolerant patients</article-title>
          <source>Allergy</source>
          <year>1998</year>
          <volume>53</volume>
          <fpage>1231</fpage>
          <lpage>1233</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1398-9995.1998.tb03854.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kosnik M, Music E, Matjaz F, Suskovic S (1998) Relative safety of meloxicam in NSAID-intolerant patients. Allergy 53:1231&#x2013;1233 <pub-id pub-id-type="pmid">9930610</pub-id></citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kruse</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ruzicka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Grewe</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib: results of oral provocation tests in patients with NSAID hypersensitivity</article-title>
          <source>Acta Derm Venereol</source>
          <year>2003</year>
          <volume>83</volume>
          <fpage>183</fpage>
          <lpage>185</lpage>
          <pub-id pub-id-type="doi">10.1080/00015550310007175</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kruse R, Ruzicka T, Grewe M (2003) Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib: results of oral provocation tests in patients with NSAID hypersensitivity. Acta Derm Venereol 83:183&#x2013;185 <pub-id pub-id-type="pmid">12816152</pub-id></citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leong</surname>
              <given-names>KP</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>CY</given-names>
            </name>
            <name>
              <surname>Thong</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>The safety of rofecoxib in patients with NSAID-induced urticaria and angioedema</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2002</year>
          <volume>109</volume>
          <fpage>S140</fpage>
          <pub-id pub-id-type="doi">10.1016/S0091-6749(02)81545-7</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Leong KP, Tang CY, Thong B (2002) The safety of rofecoxib in patients with NSAID-induced urticaria and angioedema. J Allergy Clin Immunol 109:S140 </citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levy</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Fink</surname>
              <given-names>JN</given-names>
            </name>
          </person-group>
          <article-title>Anaphylaxis to celecoxib</article-title>
          <source>Ann Allergy Asthma Immunol</source>
          <year>2001</year>
          <volume>87</volume>
          <fpage>72</fpage>
          <lpage>73</lpage>
        </citation>
        <citation citation-type="display-unstructured">Levy MB, Fink JN (2001) Anaphylaxis to celecoxib. Ann Allergy Asthma Immunol 87:72&#x2013;73 <pub-id pub-id-type="pmid">11476468</pub-id></citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liccardi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cazzola</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Giglio</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Manfredi</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Piscitelli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>D&#x2019;Amato</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and other non-steroidal anti-inflammatory drugs</article-title>
          <source>J Investig Allergol Clin Immunol</source>
          <year>2005</year>
          <volume>15</volume>
          <fpage>249</fpage>
          <lpage>253</lpage>
        </citation>
        <citation citation-type="display-unstructured">Liccardi G, Cazzola M, De Giglio C, Manfredi D, Piscitelli E, D&#x2019;Amato M et al (2005) Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and other non-steroidal anti-inflammatory drugs. J Investig Allergol Clin Immunol 15:249&#x2013;253 <pub-id pub-id-type="pmid">16433205</pub-id></citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liccardi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>D&#x2019;Amato</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Canonica</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Lobefalo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Noschese</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Piccolo</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Safety of celecoxib in patients with adverse reactions to nimesulide</article-title>
          <source>Allergy</source>
          <year>2005</year>
          <volume>60</volume>
          <fpage>708</fpage>
          <lpage>709</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1398-9995.2005.00726.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Liccardi G, D&#x2019;Amato G, Canonica GW, Lobefalo G, Noschese P, Piccolo A et al (2005) Safety of celecoxib in patients with adverse reactions to nimesulide. Allergy 60:708&#x2013;709 <pub-id pub-id-type="pmid">15813826</pub-id></citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marks</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Harrell</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma</article-title>
          <source>South Med J</source>
          <year>2001</year>
          <volume>94</volume>
          <fpage>256</fpage>
          <lpage>257</lpage>
        </citation>
        <citation citation-type="display-unstructured">Marks F, Harrell K, Fischer R (2001) Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma. South Med J 94:256&#x2013;257 <pub-id pub-id-type="pmid">11235048</pub-id></citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marshall</surname>
              <given-names>LL</given-names>
            </name>
          </person-group>
          <article-title>Angioedema associated with aspirin and rofecoxib</article-title>
          <source>Ann Pharmacother</source>
          <year>2005</year>
          <volume>39</volume>
          <fpage>944</fpage>
          <lpage>948</lpage>
          <pub-id pub-id-type="doi">10.1345/aph.1E546</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Marshall LL (2005) Angioedema associated with aspirin and rofecoxib. Ann Pharmacother 39:944&#x2013;948 <pub-id pub-id-type="pmid">15811906</pub-id></citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Hinojosa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Berges</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Camacho</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Alfaya</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma</article-title>
          <source>Chest</source>
          <year>2002</year>
          <volume>121</volume>
          <fpage>1812</fpage>
          <lpage>1817</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.121.6.1812</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Martin GC, Hinojosa M, Berges P, Camacho E, Garcia RR, Alfaya T et al (2002) Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 121:1812&#x2013;1817 <pub-id pub-id-type="pmid">12065343</pub-id></citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martin-Garcia</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hinojosa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Berges</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Camacho</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Garcia-Rodriguez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Alfaya</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients</article-title>
          <source>J Investig Allergol Clin Immunol</source>
          <year>2003</year>
          <volume>13</volume>
          <fpage>20</fpage>
          <lpage>25</lpage>
        </citation>
        <citation citation-type="display-unstructured">Martin-Garcia C, Hinojosa M, Berges P, Camacho E, Garcia-Rodriguez R, Alfaya T (2003) Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. J Investig Allergol Clin Immunol 13:20&#x2013;25 <pub-id pub-id-type="pmid">12861847</pub-id></citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mastalerz</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sanak</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gawlewicz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gielicz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Faber</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Szczeklik</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Different eicosanoid profile of the hypersensitivity reactions triggered by aspirin and celecoxib in a patient with sinusitis, asthma, and urticaria</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2006</year>
          <volume>118</volume>
          <fpage>957</fpage>
          <lpage>958</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2006.06.028</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Mastalerz L, Sanak M, Gawlewicz A, Gielicz A, Faber J, Szczeklik A (2006) Different eicosanoid profile of the hypersensitivity reactions triggered by aspirin and celecoxib in a patient with sinusitis, asthma, and urticaria. J Allergy Clin Immunol 118:957&#x2013;958 <pub-id pub-id-type="pmid">17030252</pub-id></citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matucci</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Parronchi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Vultaggio</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Brugnolo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Maggi</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients</article-title>
          <source>Allergy</source>
          <year>2004</year>
          <volume>59</volume>
          <fpage>1133</fpage>
          <lpage>1134</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1398-9995.2004.00532.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Matucci A, Parronchi P, Vultaggio A, Rossi O, Brugnolo F, Maggi E et al (2004) Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients. Allergy 59:1133&#x2013;1134 <pub-id pub-id-type="pmid">15355480</pub-id></citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Micheletto</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tognella</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Guerriero</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dal Negro</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Nasal and bronchial tolerability of Rofecoxib in patients with aspirin induced asthma</article-title>
          <source>Allerg Immunol (Paris)</source>
          <year>2006</year>
          <volume>38</volume>
          <fpage>10</fpage>
          <lpage>14</lpage>
        </citation>
        <citation citation-type="display-unstructured">Micheletto C, Tognella S, Guerriero M, Dal Negro R (2006) Nasal and bronchial tolerability of Rofecoxib in patients with aspirin induced asthma. Allerg Immunol (Paris) 38:10&#x2013;14 </citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Montalvo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Davila</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Laffond</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Moreno</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lorente</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Rofecoxib tolerance in patients with NSAID-induced reactions</article-title>
          <source>Alergol Inmunol Clin</source>
          <year>2003</year>
          <volume>18</volume>
          <fpage>214</fpage>
          <lpage>216</lpage>
        </citation>
        <citation citation-type="display-unstructured">Montalvo S, Davila I, Laffond E, Moreno E, Lorente F (2003) Rofecoxib tolerance in patients with NSAID-induced reactions. Alergol Inmunol Clin 18:214&#x2013;216 </citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morais-Almeida</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Marinho</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rosa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gaspar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rosado-Pinto</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>Multiple drug intolerance including etoricoxib</article-title>
          <source>Allergy</source>
          <year>2006</year>
          <volume>61</volume>
          <fpage>144</fpage>
          <lpage>145</lpage>
        </citation>
        <citation citation-type="display-unstructured">Morais-Almeida M, Marinho S, Rosa S, Gaspar A, Rosado-Pinto JE (2006) Multiple drug intolerance including etoricoxib. Allergy 61:144&#x2013;145 <pub-id pub-id-type="pmid">16364172</pub-id></citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Munoz-Bellido</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Terron</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Leon</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Safety of rofecoxib in nonsteroidal anti-inflammatory drugs intolerance</article-title>
          <source>Allergy</source>
          <year>2003</year>
          <volume>58</volume>
          <fpage>1072</fpage>
          <lpage>1075</lpage>
          <pub-id pub-id-type="doi">10.1034/j.1398-9995.2003.00166.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Munoz-Bellido FJ, Terron M, Leon A (2003) Safety of rofecoxib in nonsteroidal anti-inflammatory drugs intolerance. Allergy 58:1072&#x2013;1075 <pub-id pub-id-type="pmid">14510733</pub-id></citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muratore</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Calogiuri</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Calcagnile</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Quarta</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Muratore</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ventura</surname>
              <given-names>MT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tolerability of etoricoxib in patients affected by non steroidal anti-inflammatory drugs induced urticaria: a single blind placebo study on 37 subjects</article-title>
          <source>Ital J Allergy Clin Immunol</source>
          <year>2005</year>
          <volume>15</volume>
          <fpage>73</fpage>
          <lpage>79</lpage>
        </citation>
        <citation citation-type="display-unstructured">Muratore L, Calogiuri GF, Calcagnile F, Quarta E, Muratore M, Ventura MT et al (2005) Tolerability of etoricoxib in patients affected by non steroidal anti-inflammatory drugs induced urticaria: a single blind placebo study on 37 subjects. Ital J Allergy Clin Immunol 15:73&#x2013;79 </citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nahar</surname>
              <given-names>IK</given-names>
            </name>
            <name>
              <surname>Muqim</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Al Qhouti</surname>
              <given-names>BI</given-names>
            </name>
            <name>
              <surname>Al Herz</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Shehab</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Uppal</surname>
              <given-names>SS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The use of etoricoxib in patients with bronchial asthma associated with aspirin sensitivity</article-title>
          <source>Saudi Med J</source>
          <year>2006</year>
          <volume>27</volume>
          <fpage>119</fpage>
          <lpage>120</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nahar IK, Muqim AT, Al Qhouti BI, Al Herz AA, Shehab DK, Uppal SS et al (2006) The use of etoricoxib in patients with bronchial asthma associated with aspirin sensitivity. Saudi Med J 27:119&#x2013;120 <pub-id pub-id-type="pmid">16432614</pub-id></citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nekzai</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hunzelmann</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Intolerance reaction to the cyclooxygenase-2 inhibitor rofecoxib in a patient with analgesic intolerance</article-title>
          <source>H G Z Hautkr</source>
          <year>2002</year>
          <volume>77</volume>
          <fpage>246</fpage>
          <lpage>247</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1439-0353.2002.02529.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nekzai E, Hunzelmann N (2002) Intolerance reaction to the cyclooxygenase-2 inhibitor rofecoxib in a patient with analgesic intolerance. H G Z Hautkr 77:246&#x2013;247 </citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nettis</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Colanardi</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Ferrannini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tursi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs</article-title>
          <source>Ann Allergy Asthma Immunol</source>
          <year>2005</year>
          <volume>94</volume>
          <fpage>29</fpage>
          <lpage>33</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nettis E, Colanardi MC, Ferrannini A, Tursi A (2005) Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 94:29&#x2013;33 <pub-id pub-id-type="pmid">15702812</pub-id></citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nettis</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Colanardi</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Ferrannini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vacca</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tursi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs</article-title>
          <source>Ann Allergy Asthma Immunol</source>
          <year>2005</year>
          <volume>95</volume>
          <fpage>438</fpage>
          <lpage>442</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nettis E, Colanardi MC, Ferrannini A, Vacca A, Tursi A (2005) Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 95:438&#x2013;442 <pub-id pub-id-type="pmid">16312166</pub-id></citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nifosi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>COX-2 inhibitors in allergy</article-title>
          <source>Gazz Med Ital Arch Sci Med</source>
          <year>2002</year>
          <volume>161</volume>
          <fpage>109</fpage>
          <lpage>111</lpage>
        </citation>
        <citation citation-type="display-unstructured">Nifosi G (2002) COX-2 inhibitors in allergy. Gazz Med Ital Arch Sci Med 161:109&#x2013;111 </citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Novotna</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lanikova</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Dolina</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Tolerance to rofecoxib in patients with aspirin-sensitivity</article-title>
          <source>Alergie</source>
          <year>2002</year>
          <volume>4</volume>
          <fpage>149</fpage>
          <lpage>151</lpage>
        </citation>
        <citation citation-type="display-unstructured">Novotna B, Lanikova Z, Dolina J (2002) Tolerance to rofecoxib in patients with aspirin-sensitivity. Alergie 4:149&#x2013;151 </citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okie</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Raising the safety bar&#x2014;the FDA&#x2019;s coxib meeting</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>352</volume>
          <fpage>1283</fpage>
          <lpage>1285</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMp058055</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Okie S (2005) Raising the safety bar&#x2014;the FDA&#x2019;s coxib meeting. N Engl J Med 352:1283&#x2013;1285 <pub-id pub-id-type="pmid">15800221</pub-id></citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pacor</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Di Lorenzo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Biasi</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Barbagallo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Corrocher</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs</article-title>
          <source>Clin Exp Allergy</source>
          <year>2002</year>
          <volume>32</volume>
          <fpage>397</fpage>
          <lpage>400</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2222.2002.01260.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Pacor ML, Di Lorenzo G, Biasi D, Barbagallo M, Corrocher R (2002) Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Clin Exp Allergy 32:397&#x2013;400 <pub-id pub-id-type="pmid">11940070</pub-id></citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Passero</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chowdhry</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hinojosa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Martin-Garcia</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Cyclooxygenase-2 inhibitors in aspirin-sensitive asthma [2]</article-title>
          <source>Chest</source>
          <year>2003</year>
          <volume>123</volume>
          <fpage>2155</fpage>
          <lpage>2156</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.123.6.2155</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Passero M, Chowdhry S, Hinojosa M, Martin-Garcia C (2003) Cyclooxygenase-2 inhibitors in aspirin-sensitive asthma [2]. Chest 123:2155&#x2013;2156 <pub-id pub-id-type="pmid">12796206</pub-id></citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perrone</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Artesani</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Viola</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gaeta</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Caringi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Quaratino</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review</article-title>
          <source>Int Arch Allergy Immunol</source>
          <year>2003</year>
          <volume>132</volume>
          <fpage>82</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="doi">10.1159/000073268</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Perrone MR, Artesani MC, Viola M, Gaeta F, Caringi M, Quaratino D et al (2003) Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review. Int Arch Allergy Immunol 132:82&#x2013;86 <pub-id pub-id-type="pmid">14555862</pub-id></citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quiralte</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Delgado</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Saenz de San</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Lopez-Pascual</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nieto</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Ortega</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs</article-title>
          <source>Ann Allergy Asthma Immunol</source>
          <year>2004</year>
          <volume>93</volume>
          <fpage>360</fpage>
          <lpage>364</lpage>
        </citation>
        <citation citation-type="display-unstructured">Quiralte J, Delgado J, Saenz de San PB, Lopez-Pascual E, Nieto MA, Ortega N et al (2004) Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 93:360&#x2013;364 <pub-id pub-id-type="pmid">15521372</pub-id></citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quiralte</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Saenz de San</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Florido</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions</article-title>
          <source>Ann Allergy Asthma Immunol</source>
          <year>2002</year>
          <volume>89</volume>
          <fpage>63</fpage>
          <lpage>66</lpage>
        </citation>
        <citation citation-type="display-unstructured">Quiralte J, Saenz de San PB, Florido JJ (2002) Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol 89:63&#x2013;66 <pub-id pub-id-type="pmid">12141722</pub-id></citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rodriguez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Enrique</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Castello</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Mateo</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Roca</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Malek</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Tolerability of cyclooxygenase 2 inhibitors and the advisability of oral challenge [3].</article-title>
          <source>Ann Allergy Asthma Immunol</source>
          <year>2003</year>
          <volume>91</volume>
          <fpage>589</fpage>
        </citation>
        <citation citation-type="display-unstructured">Rodriguez M, Enrique E, Castello JV, De Mateo JA, Roca B, Malek T (2003) Tolerability of cyclooxygenase 2 inhibitors and the advisability of oral challenge [3]. Ann Allergy Asthma Immunol 91:589 <pub-id pub-id-type="pmid">14700447</pub-id></citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roll</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wuethrich</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Schmid-Grendelmeier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hofbauer</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ballmer-Weber</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Tolerance to celecoxib in patients with a history of adverse reactions to nonsteroidal anti-inflammatory drugs</article-title>
          <source>Swiss Med Wkly</source>
          <year>2006</year>
          <volume>136</volume>
          <fpage>684</fpage>
          <lpage>690</lpage>
        </citation>
        <citation citation-type="display-unstructured">Roll A, Wuethrich B, Schmid-Grendelmeier P, Hofbauer G, Ballmer-Weber B (2006) Tolerance to celecoxib in patients with a history of adverse reactions to nonsteroidal anti-inflammatory drugs. Swiss Med Wkly 136:684&#x2013;690 <pub-id pub-id-type="pmid">17183430</pub-id></citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanchez</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Capriles-Hulett</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Caballero-Fonseca</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Perez</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions</article-title>
          <source>Ann Allergy Asthma Immunol</source>
          <year>2001</year>
          <volume>87</volume>
          <fpage>201</fpage>
          <lpage>204</lpage>
        </citation>
        <citation citation-type="display-unstructured">Sanchez BM, Capriles-Hulett A, Caballero-Fonseca F, Perez CR (2001) Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 87:201&#x2013;204 <pub-id pub-id-type="pmid">11570615</pub-id></citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanchez-Borges</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Capriles-Hulett</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Caballero-Fonseca</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>NSAID hypersensitivity in the COX-2 inhibitor era</article-title>
          <source>Allergy Clin Immunol Int J World Allergy Org</source>
          <year>2001</year>
          <volume>211</volume>
          <fpage>218</fpage>
        </citation>
        <citation citation-type="display-unstructured">Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F (2001) NSAID hypersensitivity in the COX-2 inhibitor era. Allergy Clin Immunol Int J World Allergy Org 211&#x2013;218 </citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanchez-Borges</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Caballero-Fonseca</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Capriles-Hulett</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema</article-title>
          <source>Ann Allergy Asthma Immunol</source>
          <year>2005</year>
          <volume>95</volume>
          <fpage>154</fpage>
          <lpage>158</lpage>
        </citation>
        <citation citation-type="display-unstructured">Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A (2005) Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol 95:154&#x2013;158 <pub-id pub-id-type="pmid">16136765</pub-id></citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanchez-Borges</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Caballero-Fonseca</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Capriles-Hulett</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib</article-title>
          <source>Ann Allergy Asthma Immunol</source>
          <year>2005</year>
          <volume>94</volume>
          <fpage>34</fpage>
          <lpage>38</lpage>
        </citation>
        <citation citation-type="display-unstructured">Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A (2005) Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol 94:34&#x2013;38 <pub-id pub-id-type="pmid">15702813</pub-id></citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schellenberg</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Isserow</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor</article-title>
          <source>N Engl J Med</source>
          <year>2001</year>
          <volume>345</volume>
          <fpage>1856</fpage>
          <pub-id pub-id-type="doi">10.1056/NEJM200112203452518</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Schellenberg RR, Isserow SH (2001) Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor. N Engl J Med 345:1856 <pub-id pub-id-type="pmid">11752370</pub-id></citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schubert</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Grosse Perdekamp</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Pfeuffer</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Raith</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Brocker</surname>
              <given-names>E-B</given-names>
            </name>
            <name>
              <surname>Trautmann</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Nonsteroidal anti-inflammatory drug hypersensitivity: fable or reality?</article-title>
          <source>Eur J Dermatol</source>
          <year>2005</year>
          <volume>15</volume>
          <fpage>164</fpage>
          <lpage>167</lpage>
        </citation>
        <citation citation-type="display-unstructured">Schubert B, Grosse Perdekamp MT, Pfeuffer P, Raith P, Brocker E-B, Trautmann A (2005) Nonsteroidal anti-inflammatory drug hypersensitivity: fable or reality? Eur J Dermatol 15:164&#x2013;167 <pub-id pub-id-type="pmid">15908299</pub-id></citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Senna</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bilo</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Antonicelli</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Schiappoli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Crivellaro</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Bonadonna</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients</article-title>
          <source>Allerg Immunol (Paris)</source>
          <year>2004</year>
          <volume>36</volume>
          <fpage>215</fpage>
          <lpage>218</lpage>
        </citation>
        <citation citation-type="display-unstructured">Senna G, Bilo MB, Antonicelli L, Schiappoli M, Crivellaro MA, Bonadonna P et al (2004) Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Allerg Immunol (Paris) 36:215&#x2013;218 </citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <citation citation-type="other">Stevenson DD, Simon RA, Christiansen SC (2000) Lack of cross-reactivity between selective COX-2 inhibitors and aspirin (ASA) in ASA-sensitive asthmatics (abstract). J Allerg Clin Immunol S273</citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stevenson</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2001</year>
          <volume>108</volume>
          <fpage>47</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="doi">10.1067/mai.2001.116290</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Stevenson DD, Simon RA (2001) Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 108:47&#x2013;51 <pub-id pub-id-type="pmid">11447381</pub-id></citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stevenson</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Zuraw</surname>
              <given-names>BL</given-names>
            </name>
          </person-group>
          <article-title>Pathogenesis of aspirin-exacerbated respiratory disease</article-title>
          <source>Clin Rev Allergy Immunol</source>
          <year>2003</year>
          <volume>24</volume>
          <fpage>169</fpage>
          <lpage>188</lpage>
          <pub-id pub-id-type="doi">10.1385/CRIAI:24:2:169</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Stevenson DD, Zuraw BL (2003) Pathogenesis of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol 24:169&#x2013;188 <pub-id pub-id-type="pmid">12668897</pub-id></citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Szczeklik</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nizankowska</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bochenek</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Nagraba</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mejza</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Swierczynska</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Safety of a specific COX-2 inhibitor in aspirin-induced asthma</article-title>
          <source>Clin Exp Allergy</source>
          <year>2001</year>
          <volume>31</volume>
          <fpage>219</fpage>
          <lpage>225</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2222.2001.01075.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M (2001) Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 31:219&#x2013;225 <pub-id pub-id-type="pmid">11251623</pub-id></citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vaghi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bernardi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Grassi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Capato</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cicchitto</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sestini</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tolerance of two cox2inhibitors, rofecoxib and celecoxib, in aspirin sensitive asthmatics.</article-title>
          <source>Eur Respir J</source>
          <year>2001</year>
          <volume>18</volume>
          <fpage>428s</fpage>
        </citation>
        <citation citation-type="display-unstructured">Vaghi A, De Bernardi G, Grassi N, Capato S, Cicchitto G, Sestini P et al (2001) Tolerance of two cox2inhibitors, rofecoxib and celecoxib, in aspirin sensitive asthmatics. Eur Respir J 18:428s </citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Valero</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Baltasar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Enrique</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pau</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Dordal</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Cistero</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>NSAID-sensitive patients tolerate rofecoxib</article-title>
          <source>Allergy</source>
          <year>2002</year>
          <volume>57</volume>
          <fpage>1214</fpage>
          <lpage>1215</lpage>
          <pub-id pub-id-type="doi">10.1034/j.1398-9995.2002.23893_6.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Valero A, Baltasar M, Enrique E, Pau L, Dordal MT, Cistero A et al (2002) NSAID-sensitive patients tolerate rofecoxib. Allergy 57:1214&#x2013;1215 <pub-id pub-id-type="pmid">12464059</pub-id></citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Valero</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Enrique</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Baltasar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cistero</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Marti</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Picado</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Celecoxib in NSAID-induced cutaneous and respiratory adverse reactions</article-title>
          <source>Med Clin (Barc)</source>
          <year>2003</year>
          <volume>121</volume>
          <fpage>695</fpage>
          <lpage>696</lpage>
          <pub-id pub-id-type="doi">10.1157/13054598</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Valero A, Enrique E, Baltasar M, Cistero A, Marti E, Picado C (2003) Celecoxib in NSAID-induced cutaneous and respiratory adverse reactions. Med Clin (Barc) 121:695&#x2013;696 <pub-id pub-id-type="pmid">14651817</pub-id></citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Viola</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Quaratino</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gaeta</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Caringi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Valluzzi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Caruso</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to nonsteroidal anti-inflammatory drugs</article-title>
          <source>Int Arch Allergy Immunol</source>
          <year>2005</year>
          <volume>137</volume>
          <fpage>145</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="doi">10.1159/000085794</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Viola M, Quaratino D, Gaeta F, Caringi M, Valluzzi R, Caruso C et al (2005) Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 137:145&#x2013;150 <pub-id pub-id-type="pmid">15897671</pub-id></citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Viola</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Quaratino</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Volpetti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gaeta</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Romano</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Parecoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2006</year>
          <volume>117</volume>
          <fpage>1189</fpage>
          <lpage>1191</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2006.02.011</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Viola M, Quaratino D, Volpetti S, Gaeta F, Romano A (2006) Parecoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol 117:1189&#x2013;1191 <pub-id pub-id-type="pmid">16675352</pub-id></citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Woessner</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Stevenson</surname>
              <given-names>DD</given-names>
            </name>
          </person-group>
          <article-title>The safety of celecoxib in patients with aspirin-sensitive asthma</article-title>
          <source>Arthritis Rheum</source>
          <year>2002</year>
          <volume>46</volume>
          <fpage>2201</fpage>
          <lpage>2206</lpage>
          <pub-id pub-id-type="doi">10.1002/art.10426</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Woessner KM, Simon RA, Stevenson DD (2002) The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 46:2201&#x2013;2206 <pub-id pub-id-type="pmid">12209526</pub-id></citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Woessner</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Stevenson</surname>
              <given-names>DD</given-names>
            </name>
          </person-group>
          <article-title>Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease</article-title>
          <source>Ann Allergy Asthma Immunol</source>
          <year>2004</year>
          <volume>93</volume>
          <fpage>339</fpage>
          <lpage>344</lpage>
        </citation>
        <citation citation-type="display-unstructured">Woessner KM, Simon RA, Stevenson DD (2004) Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 93:339&#x2013;344 <pub-id pub-id-type="pmid">15521369</pub-id></citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wolfe</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Lichtenstein</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.</article-title>
          <source>N Engl J Med</source>
          <year>1999</year>
          <volume>340</volume>
          <fpage>1888</fpage>
          <lpage>1899</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199906173402407</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Wolfe MM, Lichtenstein DR, Singh G (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340:1888&#x2013;1899 <pub-id pub-id-type="pmid">10369853</pub-id></citation>
      </ref>
      <ref id="CR86">
        <label>86.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wyplosz</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Vautier</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lillo-Le Louet</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Capron</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Tolerance of diclofenac after hypersensitivity to celecoxib and to nabumetone</article-title>
          <source>Br J Clin Pharmacol</source>
          <year>2006</year>
          <volume>61</volume>
          <fpage>474</fpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2125.2005.02576.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Wyplosz B, Vautier S, Lillo-Le Louet A, Capron L (2006) Tolerance of diclofenac after hypersensitivity to celecoxib and to nabumetone. Br J Clin Pharmacol 61:474 <pub-id pub-id-type="pmid">16542210</pub-id></citation>
      </ref>
      <ref id="CR87">
        <label>87.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoshida</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ishizaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Onuma</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shoji</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nakagawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Amayasu</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Selective cyclo-oxygenase 2 inhibitor in patients with aspirin-induced asthma [2]</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2000</year>
          <volume>106</volume>
          <fpage>1201</fpage>
          <lpage>1202</lpage>
          <pub-id pub-id-type="doi">10.1067/mai.2000.110926</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Yoshida S, Ishizaki Y, Onuma K, Shoji T, Nakagawa H, Amayasu H (2000) Selective cyclo-oxygenase 2 inhibitor in patients with aspirin-induced asthma [2]. J Allergy Clin Immunol 106:1201&#x2013;1202 <pub-id pub-id-type="pmid">11112909</pub-id></citation>
      </ref>
      <ref id="CR88">
        <label>88.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zembowicz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mastalerz</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Setkowicz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Radziszewski</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Szczeklik</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs</article-title>
          <source>Arch Dermatol</source>
          <year>2003</year>
          <volume>139</volume>
          <fpage>1577</fpage>
          <lpage>1582</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.139.12.1577</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A (2003) Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol 139:1577&#x2013;1582 <pub-id pub-id-type="pmid">14676074</pub-id></citation>
      </ref>
      <ref id="CR89">
        <label>89.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zollner</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Ahlbach</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kaufmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Boehncke</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
          <article-title>Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents</article-title>
          <source>Dtsch Med Wochenschr</source>
          <year>2001</year>
          <volume>126</volume>
          <fpage>386</fpage>
          <lpage>388</lpage>
          <pub-id pub-id-type="doi">10.1055/s-2001-12640</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Zollner TM, Ahlbach S, Kaufmann R, Boehncke WH (2001) Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents. Dtsch Med Wochenschr 126:386&#x2013;388 <pub-id pub-id-type="pmid">11332239</pub-id></citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>